Applied Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Les D. Funtleyder
- Full Time Employees
- 35
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 545 Fifth Avenue New York City NY United States of America 10017
- IPO Date
- May 14, 2019
- CIK
- 0001697532
- Website
- appliedtherapeutics.com
- Similar Companies
- Business
- Applied Therapeutics, Inc. Applied Therapeutics, Inc. (Nasdaq: APLT) is a clinical-stage biopharmaceutical company that develops novel drug candidates targeting validated molecular pathways in indications of high unmet medical need, particularly rare metabolic diseases; its lead product candidate, govorestat (AT-007), a central nervous system-penetrant aldose reductase inhibitor (ARI), advances in Phase 3 for classic galactosemia with positive 12-month interim data, sorbitol dehydrogenase (SORD) deficiency in Charcot-Marie-Tooth disease, and phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG) with Phase 2 readiness and expanded access programs; additional pipeline assets include AT-001 (caficrestat), an ARI in Phase 3 for diabetic cardiomyopathy and diabetic peripheral neuropathy, and AT-003, a preclinical/Phase 1-ready ARI for diabetic retinopathy with strong retinal penetrance. The company, founded in 2016 and headquartered in New York, operates primarily in the United States, focusing on rare diseases through advanced crystallography-enabled ARI compounds that enhance binding specificity and reduce off-target effects. In November 2025, Applied Therapeutics announces its Board initiates a strategic alternatives process to maximize shareholder value, encompassing mergers, acquisitions, partnerships, joint ventures, and licensing arrangements amid a 46% workforce reduction for cost containment; it completes a Type C meeting with the FDA in Q3 2025 on galactosemia and plans another to discuss potential Phase 3 design, while entering a $75 million equity sales agreement with Cantor Fitzgerald.
Analyzing Cartesian Therapeutics (NASDAQ:RNAC) and Applied Therapeutics (NASDAQ:APLT)
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
Applied Therapeutics Inc. (NASDAQ:APLT) Short Interest Update
Here's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now
APLT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Applied Therapeutics, Inc. is Fair to Shareholders
Cycle Pharmaceuticals to Acquire Applied Therapeutics
Applied Therapeutics (APLT) Upgraded to Buy: Here's Why
Applied Therapeutics Announces Corporate Updates
Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain
Applied Therapeutics Reports Third Quarter 2025 Financial Results
Halper Sadeh LLC Encourages Applied Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Applied Therapeutics Provides Update Following Meeting with FDA
Applied Therapeutics Reports Second Quarter 2025 Financial Results
Applied Therapeutics Announces Key Leadership Appointments
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Applied Therapeutics Reports First Quarter 2025 Financial Results